Concepedia

S. Hibbitts

SH

9

Publications

1.1K

Citations

9

H-Index

2001

Active since

Affiliations

University of Virginia Health System(Current)

University of Virginia

Cardiff University

S. Hibbitts is an author at University of Virginia Health System specializing in medicine, vaccination, and tumor immunity.

Top concepts

Publications per year

2001–2009

9

Publications

9

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2003 · 321 citations

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Craig L. Slingluff, Galina V. Yamshchikov, Patrice Y. Neese et al. · PubMed · 2001 · 229 citations

, , +18

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

Craig L. Slingluff, Gina R. Petroni, Kimberly A. Chianese‐Bullock et al. · Clinical Cancer Research · 2007 · 160 citations · Full text

Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2004 · 146 citations · Full text

MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma

Kimberly A. Chianese‐Bullock, Jennifer Pressley, Courtney F. Garbee et al. · The Journal of Immunology · 2005 · 124 citations

Rows per page

1–5 of 9